Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03152643Not ApplicableCompleted

Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer

Role: collaborator

NCT03824990Not ApplicableCompleted

Multi-center Clinical Study on Neonatal Hyperbilirubinemia

Role: collaborator

NCT03118141Not ApplicableUnknown

Cumulative Live Birth Rate With eSET After Preimplantation Genetic Screening Versus Conventional In-vitro Fertilization

Role: collaborator

NCT03809221Phase 4Unknown

The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation

Role: collaborator

NCT01762189Completed

The Incidence and Risk Factors of Neonatal Hyperbilirubinemia in Term and Late-preterm Chinese Infants

Role: collaborator

NCT01763632Completed

Development of TcB Nomogram to Identify Neonatal Hyperbilirubinemia in Term and Late-preterm Infants

Role: collaborator

All 6 trials loaded